Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A

Molecular Pharmaceutics

Volumn 11, Issue 10, 2014, Pages 3421-3430

  Yang, Jihong ^a   Wang, Xiangdan ^a   Fuh, Germaine ^a   Yu, Lanlan ^a   Wakshull, Eric ^a   Khosraviani, Mehraban ^a   Day, Eric S ^a   Demeule, Barthélemy ^a   Liu, Jun ^a   Shire, Steven J ^a   Ferrara, Napoleone ^a,b   Yadav, Sandeep ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

affinity; aflibercept; analytical ultracentrifugation; bevacizumab; ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; RANIBIZUMAB; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN A; HYBRID PROTEIN; PROTEIN BINDING; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; CAPILLARY ENDOTHELIAL CELL; CELL PROLIFERATION; DISSOCIATION CONSTANT; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; EQUILIBRIUM CONSTANT; IC50; IN VITRO STUDY; NONHUMAN; RETINA CELL; SEDIMENTATION; SEDIMENTATION RATE; SYSTEMIC CIRCULATION; ULTRACENTRIFUGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BOVINE; CELL LINE; CYTOLOGY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CATTLE; CELL LINE; CELL PROLIFERATION; ENDOTHELIAL CELLS; PROTEIN BINDING; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; ULTRACENTRIFUGATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907979001     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500160v     Document Type: Article

References (34)

1. Ferrara, N.; Damico, L.; Shams, N.; Lowman, H.; Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 2006, 26 (8) 859-870
2. Lowe, J.; Araujo, J.; Yang, J.; Reich, M.; Oldendorp, A.; Shiu, V.; Quarmby, V.; Lowman, H.; Lien, S.; Gaudreault, J.; Maia, M. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp. Eye Res. 2007, 85 (4) 425-430
3. Presta, L. G.; Chen, H.; OConnor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res. 1997, 57 (20) 4593-4599
4. Papadopoulos, N.; Martin, J.; Ruan, Q.; Rafique, A.; Rosconi, M. P.; Shi, E.; Pyles, E. A.; Yancopoulos, G. D.; Stahl, N.; Wiegand, S. J. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 2012, 15 (2) 171-185
5. Handbook of Surface Plasmon Resonance; RSC Publishing: Enschede, the Netherlands, 2007.
6. Trilling, A. K.; Harmsen, M. M.; Ruigrok, V. J. B.; Zuilhof, H.; Beekwilder, J. The effect of uniform capture molecule orientation on biosensor sensitivity: Dependence on analyte properties Biosens. Bioelectron. 2013, 40 (1) 219-226
7. OShannessy, D. J. Determination of kinetic rate and equilibrium binding constants for macromolecular interactions: A critique of the surface plasmon resonance literature Curr. Opin. Biotechnol. 1994, 5 (1) 65-71
8. Yadav, S.; Liu, J.; Scherer, T. M.; Gokarn, Y.; Demeule, B.; Kanai, S.; Andya, J. D.; Shire, S. J. Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals Biophys. Rev. 2013, 5, 121-136
9. Kroe, R. R.; Laue, T. M. NUTS and BOLTS: Applications of fluorescence-detected sedimentation Anal. Biochem. 2009, 390 (1) 1-13
10. MacGregor, I. K.; Anderson, A. L.; Laue, T. M. Fluorescence detection for the XLI analytical ultracentrifuge Biophys. Chem. 2004, 108 (1-3) 165-185
11. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: A VEGF blocker with potent antitumor effects Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (17) 11393-11398
12. Yu, L.; Liang, X. H.; Ferrara, N. Comparing protein VEGF inhibitors: In vitro biological studies Biochem. Biophys. Res. Commun. 2011, 408 (2) 276-281
13. LUCENTIS (ranibizumab injection). Highlights of Prescribing Information. Available at http://www.gene.com/download/pdf/lucentisprescribing.pdf.
14. EYLEA (aflibercept injection). Highlights of Prescribing Information. Available at http://www.regeneron.com/Eylea/eylea-fpi.pdf.
15. Schuck, P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling Biophys. J. 2000, 78 (3) 1606-1619
16. Leung, D. W.; Cachianes, G.; Kuang, W. J.; Goeddel, D. V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen Science 1989, 246 (4935) 1306-1309
17. Karlsson, R.; Falt, A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors J. Immunol. Methods 1997, 200 (1-2) 121-133
18. Muller, K. M.; Arndt, K. M.; Pluckthun, A. Model and simulation of multivalent binding to fixed ligands Anal. Biochem. 1998, 261 (2) 149-158
19. Schuck, P.; Perugini, M. A.; Gonzales, N. R.; Howlett, G. J.; Schubert, D. Size-distribution analysis of proteins by analytical ultracentrifugation: Strategies and application to model systems Biophys. J. 2002, 82 (2) 1096-1111
20. Schuck, P. On computational approaches for size-and-shape distributions from sedimentation velocity analytical ultracentrifugation Eur. Biophys J. 2010, 39 (8) 1261-1275
21. Gabrielson, J. P.; Arthur, K. K.; Stoner, M. R.; Winn, B. C.; Kendrick, B. S.; Razinkov, V.; Svitel, J.; Jiang, Y.; Voelker, P. J.; Fernandes, C. A.; Ridgeway, R. Precision of protein aggregation measurements by sedimentation velocity analytical ultracentrifugation in biopharmaceutical applications Anal. Biochem. 2010, 396 (2) 231-241
22. Cannon, M. J.; Myska, D. G. Surface Plasmon Resonance. In Methods for Structural Analysis of Protein Pharmaceuticals; Jiskoot, W.; Crommelin, D., Eds.; AAPS Press: Arlington, VA, 2005; Vol. 3, pp 527-544.
23. Drake, A. W.; Myszka, D. G.; Klakamp, S. L. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods Anal. Biochem. 2004, 328 (1) 35-43
24. Heier, J. S.; Brown, D. M.; Chong, V.; Korobelnik, J. F.; Kaiser, P. K.; Nguyen, Q. D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U.; VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 2012, 119 (12) 2537-2548
25. Schmidt-Erfurth, U.; Kaiser, P. K.; Korobelnik, J. F.; Brown, D. M.; Chong, V.; Nguyen, Q. D.; Ho, A. C.; Ogura, Y.; Simader, C.; Jaffe, G. J.; Slakter, J. S.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Sowade, O.; Zeitz, O.; Norenberg, C.; Sandbrink, R.; Heier, J. S. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies Ophthalmology 2014, 121 (1) 193-201
26. Chakravarthy, U.; Harding, S. P.; Rogers, C. A.; Downes, S. M.; Lotery, A. J.; Wordsworth, S.; Reeves, B. C.; IVAN Study Investigators Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial Ophthalmology 2012, 119 (7) 1399-1411
27. Martin, D. F.; Maguire, M. G.; Ying, G. S.; Grunwald, J. E.; Fine, S. L.; Jaffe, G. J.; CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N. Engl. J. Med. 2011, 364 (20) 1897-1908
28. Martin, D. F.; Maguire, M. G.; Fine, S. L.; Ying, G. S.; Jaffe, G. J.; Grunwald, J. E.; Toth, C.; Redford, M.; Ferris, F. L., 3rd. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results Ophthalmology 2012, 119 (7) 1388-1398
29. Avery, R. L.; Castellarin, A. A.; Steinle, N. C.; Dhoot, S. D.; Pieramici, D. J.; See, R.; Couvillion, S.; Nasir, M. A.; Rabena, M. D.; Le, K.; Maia, M.; Visich, J. E. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Br. J. Ophthalmol. 2014, 10.1136/bjophthalmol-2014-305252
30. Avery, R. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br. J. Ophthalmol. 2014, 98 (Suppl 1) i7-i10
31. Le, K.; Lu, T.; Visich, J. A semi-mechanistic PKPD model describing visual acuity as a function of the affinity and intravitreal half-life of intraocular anti-VEGF agents in age-related macular degeneration. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Indianapolis, IN, 2013.
32. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2007, 6 (3) 249-249
33. Yu, Y. J.; Zhang, Y.; Kenrick, M.; Hoyte, K.; Luk, W.; Lu, Y. M.; Atwal, J.; Elliott, J. M.; Prabhu, S.; Watts, R. J.; Dennis, M. S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 2011, 3 (84) 1-8
34. Heier, J. S.; Brown, D. M.; Chongf, V.; Korobelnik, J. F.; Kaiser, P. K.; Nguyen, Q. D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U.; VIEW 1 and VIEW 2 Study Groups Erratum: Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 2013, 120 (1) 209-210